Document:

Exhibit
4.2

 

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION
IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.

 

WARRANT
TO PURCHASE SHARES OF PREFERRED STOCK

 

For
the Consideration stipulated in that certain Warrant Purchase Agreement dated as of March 8, 2021 between the Company and Holder
(the “Purchase Agreement”), the receipt and sufficiency of which is hereby acknowledged, this Warrant is issued
to Aron English (the “Holder”) by ANEBULO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).

 

Capitalized
terms not defined herein shall have the meaning set forth in the Purchase Agreement.

 

1.
Purchase of Shares.

 

(a)
Number of Shares. Subject to the terms and conditions set forth herein and set forth in the Purchase Agreement, the Holder
is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall
notify the Holder in writing), to purchase from the Company up to such number of shares of the Company’s Series A Preferred
Stock, $0.001 par value per share, as is set forth next to Holder’s name in the Schedule of Purchasers attached to that
certain Series A Preferred Stock Purchase Agreement by and among the Company and the purchasers named therein, as amended from
time to time, and as adjusted pursuant to Section 7 hereof (the “Exercise Shares”).

 

(b)
Exercise Price. The purchase price per share for the Exercise Shares issuable pursuant to this Section 1 shall be $10.11,
as adjusted pursuant to Section 7 hereof. Such purchase price, as adjusted from time to time, is herein referred to as (the “Exercise
Price”).

 

2.
Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the date hereof
and ending at 5:00 p.m. eastern standard time on the three year anniversary of the date of issuance (the “Exercise Period”)
provided, however, that this Warrant shall no longer be exercisable and shall become null and void upon the consummation
of a Corporate Transaction or Initial Public Offering. In the event of a Corporate Transaction or Initial Public Offering, the
Company shall notify the Holder at least ten (10) days prior to the consummation of such Corporate Transaction or Initial Public
Offering.

 

3.
Method of Exercise.

 

(a)
While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise, in whole or
in part, the purchase rights evidenced hereby. Such exercise shall be effected by:

 

(i)
the surrender of the Warrant, together with a duly executed copy of the Notice of Exercise attached hereto, to the Secretary of
the Company at its principal office (or at such other place as the Company shall notify the Holder in writing); and

 

    	 

    	 

    

 

(ii)
the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Exercise Shares being purchased.

 

(b)
Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which
this Warrant is surrendered to the Company as provided in Section 3(a) above. At such time, the person or persons in whose name
or names any certificate for the Exercise Shares shall be issuable upon such exercise as provided in Section 3(c) below shall
be deemed to have become the holder or holders of record of the Exercise Shares represented by such certificate.

 

(c)
As soon as practicable after the exercise of this Warrant in whole or in part, the Company at its expense will cause to be issued
in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes)
may direct:

 

(i)
a certificate or certificates for the number of Exercise Shares to which such Holder shall be entitled, and

 

(ii)
in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate
on the face or faces thereof for the number of Exercise Shares equal to the number of such Exercise Shares called for on the face
of this Warrant minus the number of Exercise Shares purchased by the Holder upon all exercises made in accordance with Section
3(a) above or Section 4 below.

 

(d)
Notwithstanding the provisions of Section 2 if the Holder has not exercised this Warrant prior to the closing of a Corporate Transaction
or an Initial Public Offering, this Warrant shall automatically be deemed to be exercised in full in the manner set forth in Section
4, without any further action on behalf of the Holder, immediately prior to such closing.

 

4.
Net Exercise. In lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value
of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together
with notice of such election (a “Net Exercise”). A Holder who Net Exercises shall have the rights described
in Sections 3(b) and 3(c) hereof, and the Company shall issue to such Holder a number of Exercise Shares computed using the following
formula:

 

 

Where

 

	 	X
    = 	The
    number of Exercise Shares to be issued to the Holder.
	 	 	 
	 	Y
    = 	The
    number of Exercise Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion
    of the Warrant being cancelled (at the date of such calculation).
	 	 	 
	 	A
    = 	The
    fair market value of one (1) Exercise Share (at the date of such calculation).
	 	 	 
	 	B
    = 	The
    Exercise Price (as adjusted to the date of such calculations).

 

    	 

    	 

    

 

For
purposes of this Section 4, the fair market value of an Exercise Share shall mean the average of the closing price of the Exercise
Shares quoted in the over-the-counter market in which the Exercise Shares are traded or the closing price quoted on any exchange
or electronic securities market on which the Exercise Shares are listed, whichever is applicable, as published in The Wall
Street Journal for the thirty (30) trading days prior to the date of determination of fair market value (or such shorter period
of time during which such Exercise Shares were traded over-the-counter or on such exchange). In the event that this Warrant is
exercised pursuant to this Section 4 in connection with the Company’s Initial Public Offering, the fair market value per
Exercise Share shall be the per share offering price to the public of the Company’s Initial Public Offering. If the Exercise
Shares are not traded on the over-the-counter market, an exchange or an electronic securities market, the fair market value shall
be the price per Exercise Share that the Company could obtain from a willing buyer for Exercise Shares sold by the Company from
authorized but unissued Exercise Shares, as such prices shall be determined in good faith by the Company’s Board of Directors.

 

5.
Covenants of the Company.

 

(a)
Notices of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities
for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which
is the same as cash dividends paid in previous quarters or a stock dividend) or other distribution, the Company shall mail to
the Holder, at least ten (10) days prior to such record date, a notice specifying the date on which any such record is to be taken
for the purpose of such dividend or distribution.

 

(b)
Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance in accordance with the terms hereof, be validly issued
and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof.
The Company further covenants and agrees that the Company will at all times during the Exercise Period have authorized and reserved,
free from preemptive rights, a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights represented
by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of Preferred Stock shall
not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its
counsel, be necessary to increase its authorized but unissued shares of Preferred Stock to such number of shares as shall be sufficient
for such purposes.

 

(c)
Registration Rights. The provisions concerning piggyback registration of certain Registrable Securities held by the Holder
that are set forth on Exhibit 1 attached to this Warrant are incorporated into and made a part of this Warrant.

 

6.
Adjustment of Exercise Price and Number of Exercise Shares. The number and kind of Exercise Shares purchasable upon
exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

 

(a)
Subdivisions, Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration
of this Warrant subdivide its Preferred Stock, by split-up or otherwise, or combine its Preferred Stock, or issue additional shares
of its Preferred Stock as a dividend with respect to any shares of its Preferred Stock, the number of Exercise Shares issuable
on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or
proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price payable
per share, but the aggregate Exercise Price payable for the total number of Exercise Shares purchasable under this Warrant (as
adjusted) shall remain the same. Any adjustment under this Section 6(a) shall become effective at the close of business on the
date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record
date is fixed, upon the making of such dividend.

 

    	 

    	 

    

 

(b)
Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in
the capital stock of the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section
6(a) above), then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly
executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder
shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon
the exercise of this Warrant, the kind and amount of shares of stock and other securities or property receivable in connection
with such reclassification, reorganization or change by a holder of the same number and type of securities as were purchasable
as Exercise Shares by the Holder immediately prior to such reclassification, reorganization or change. In any such case appropriate
provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter
be applicable with respect to any shares of stock or other securities or property deliverable upon exercise hereof, and appropriate
adjustments shall be made to the Exercise Price per Exercise Share payable hereunder, provided the aggregate Exercise Price
shall remain the same.

 

(c)
Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise
of the Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Exercise
Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

 

7.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of
the Exercise Price then in effect.

 

8.
No Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder
with respect to the Exercise Shares, including (without limitation) the right to vote such Exercise Shares, receive dividends
or other distributions thereon, exercise preemptive rights or be notified of stockholder meetings, and except as otherwise provided
in this Warrant or the Purchase Agreement, such Holder shall not be entitled to any stockholder notice or other communication
concerning the business or affairs of the Company.

 

9.
Transfer of Warrant. Subject to compliance with applicable federal and state securities laws and any other contractual
restrictions between the Company and the Holder contained in the Purchase Agreement (including but not limited to Sections 6.7
and 8.13), this Warrant and all rights hereunder are transferable in whole or in part by the Holder to any person or entity upon
written notice to the Company. Within a reasonable time after the Company’s receipt of an executed Assignment Form in the
form attached hereto, the transfer shall be recorded on the books of the Company upon the surrender of this Warrant, properly
endorsed, to the Company at its principal offices, and the payment to the Company of all transfer taxes and other governmental
charges imposed on such transfer. In the event of a partial transfer, the Company shall issue to the new holders one or more appropriate
new warrants.

 

10.
Governing Law; Arbitration. This Warrant shall be governed by and construed under the laws of the State of Delaware
as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware. Any unresolved
controversy or claim arising out of or relating to this Warrant, except as (a) otherwise provided in this Warrant, or (b) any
such controversies or claims arising out of either party’s intellectual property rights for which a provisional remedy or
equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no
agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration
Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions
of the type provided for in this Warrant and who is chosen by the AAA. The arbitration shall take place in Wilmington, Delaware,
in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and
may be entered in any court having jurisdiction thereof.

 

    	 

    	 

    

 

11.
Successors and Assigns. The terms and provisions of this Warrant and the Purchase Agreement shall inure to the benefit
of, and be binding upon, the Company and the holders hereof and their respective successors and assigns.

 

12.
Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be
considered in construing or interpreting this Warrant.

 

13.
Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile
if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit
with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications
shall be sent to the respective parties at the following addresses (or at such other addresses as shall be specified by notice
given in accordance with this Section 13):

 

	If
    to the Company:	Anebulo
    Pharmaceuticals, Inc. 
	 	1415
    Ranch Road 620 South, 
	 	Suite
    201
	 	Lakeway,
    Texas 78734
	 	Attention:
    CEO
	 	 
	If
    to Holder:	At
    the address shown on the signature page hereto.

 

14.
Amendments and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any term of this Warrant, the resolution
of any controversy or claim arising out of or relating to this Warrant and the provision of notice shall be conducted pursuant
to the terms of the Purchase Agreement.

 

15.
Severability. If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall
be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall
be enforceable in accordance with its terms.

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Warrant as of the date first written above.

 

	 	ANEBULO
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/
    Daniel Schneeberger       
	 	Name:	Daniel
    Schneeberger
	 	Title:	Chief
    Executive Officer

 

	 	ACKNOWLEDGED
    AND AGREED:
	 	 
	 	HOLDER:
	 	 
	 	/s/
    Aron English        
	 	Name:	Aron
    English             

 

    	 

    	 

    

 

EXHIBIT
1 TO WARRANT

 

1.
Definitions. For purposes of this Exhibit:

 

1.1
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including without limitation any general partner, managing member,
officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general
partners or managing members of, or shares the same management company with, such Person.

 

1.2
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability
(or any action in respect thereof) arises out of or is based upon: (a) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto; (b) an omission or alleged omission to state therein a material fact required
to be stated therein, or necessary to make the statements therein not misleading; or (c) any violation or alleged violation by
the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law,
or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.3
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.

 

1.4
“Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.5
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

    	 

    	 

    

 

NOTICE
OF EXERCISE

 

ANEBULO
PHARMACEUTICALS, INC.

Attention:
Corporate Secretary

 

The
undersigned hereby elects to purchase, pursuant to the provisions of the Warrant, as follows:

 

	 	[  ]	__________
    shares of Preferred Stock pursuant to the terms of the attached Warrant, and tenders herewith payment in cash of the Exercise
    Price of such Exercise Shares in full, together with all applicable transfer taxes, if any.
	 	 	 
	 	[  ]	Net
    Exercise the attached Warrant with respect to __________ Exercise Shares.

 

The
undersigned hereby represents and warrants that Representations and Warranties in Section 6 of the Purchase Agreement are true
and correct as of the date hereof.

 

	 	 	HOLDER:
	 	 	 	 
	Date:	 	By:	             

 

	 	Address:	 
	 	 

 

	Name
    in which shares should be registered:	 
	 	 

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information.

Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:__________________________________________________________________________________________

(Please
Print)

 

Address:________________________________________________________________________________________

(Please
Print)

 

Dated:______________________________________________

 

Holder’s
Signature:________________________________________________________________________________

 

Holder’s
Address:_________________________________________________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant. Officers of corporations
and those acting in a fiduciary or other representative capacity should provide proper evidence of authority to assign the foregoing
Warrant.Exhibit
4.3

 

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION
IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.

 

WARRANT
TO PURCHASE SHARES OF PREFERRED STOCK

 

For
the Consideration stipulated in that certain Warrant Purchase Agreement dated as of March 8, 2021 between the Company and Holder
(the “Purchase Agreement”), the receipt and sufficiency of which is hereby acknowledged, this Warrant is issued
to 22NW, LP (the “Holder”) by ANEBULO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).

 

Capitalized
terms not defined herein shall have the meaning set forth in the Purchase Agreement.

 

1. Purchase
of Shares.

 

(a) Number
of Shares. Subject to the terms and conditions set forth herein and set forth in the Purchase Agreement, the Holder is entitled,
upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the
Holder in writing), to purchase from the Company up to such number of shares of the Company’s Series A Preferred Stock,
$0.001 par value per share, as is set forth next to Holder’s name in the Schedule of Purchasers attached to that certain
Series A Preferred Stock Purchase Agreement by and among the Company and the purchasers named therein, as amended from time to
time, and as adjusted pursuant to Section 7 hereof (the “Exercise Shares”).

 

(b) Exercise
Price. The purchase price per share for the Exercise Shares issuable pursuant to this Section 1 shall be $10.11, as adjusted
pursuant to Section 7 hereof. Such purchase price, as adjusted from time to time, is herein referred to as (the “Exercise
Price”).

 

2. Exercise
Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the date hereof and ending
at 5:00 p.m. eastern standard time on the three year anniversary of the date of issuance (the “Exercise Period”)
provided, however, that this Warrant shall no longer be exercisable and shall become null and void upon the consummation
of a Corporate Transaction or Initial Public Offering. In the event of a Corporate Transaction or Initial Public Offering, the
Company shall notify the Holder at least ten (10) days prior to the consummation of such Corporate Transaction or Initial Public
Offering.

 

3. Method
of Exercise.

 

(a) While
this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise, in whole or in part,
the purchase rights evidenced hereby. Such exercise shall be effected by:

 

(i) the
surrender of the Warrant, together with a duly executed copy of the Notice of Exercise attached hereto, to the Secretary of the
Company at its principal office (or at such other place as the Company shall notify the Holder in writing); and

 

    	 

    	 

    

 

(ii) the
payment to the Company of an amount equal to the aggregate Exercise Price for the number of Exercise Shares being purchased.

 

(b) Each
exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which
this Warrant is surrendered to the Company as provided in Section 3(a) above. At such time, the person or persons in whose name
or names any certificate for the Exercise Shares shall be issuable upon such exercise as provided in Section 3(c) below shall
be deemed to have become the holder or holders of record of the Exercise Shares represented by such certificate.

 

(c) As
soon as practicable after the exercise of this Warrant in whole or in part, the Company at its expense will cause to be issued
in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes)
may direct:

 

(i) a
certificate or certificates for the number of Exercise Shares to which such Holder shall be entitled, and

 

(ii) in
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate
on the face or faces thereof for the number of Exercise Shares equal to the number of such Exercise Shares called for on the face
of this Warrant minus the number of Exercise Shares purchased by the Holder upon all exercises made in accordance with Section
3(a) above or Section 4 below.

 

(d) Notwithstanding
the provisions of Section 2 if the Holder has not exercised this Warrant prior to the closing of a Corporate Transaction or an
Initial Public Offering, this Warrant shall automatically be deemed to be exercised in full in the manner set forth in Section
4, without any further action on behalf of the Holder, immediately prior to such closing.

 

4. Net
Exercise. In lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value of this
Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together
with notice of such election (a “Net Exercise”). A Holder who Net Exercises shall have the rights described
in Sections 3(b) and 3(c) hereof, and the Company shall issue to such Holder a number of Exercise Shares computed using the following
formula:

 

 

Where

 

	 	X
    =	The
    number of Exercise Shares to be issued to the Holder.
	 	 	 
	 	Y
    =	The
    number of Exercise Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion
    of the Warrant being cancelled (at the date of such calculation).
	 	 	 
	 	A
    =	The
    fair market value of one (1) Exercise Share (at the date of such calculation).
	 	 	 
	 	B
    =	The
    Exercise Price (as adjusted to the date of such calculations).

 

For
purposes of this Section 4, the fair market value of an Exercise Share shall mean the average of the closing price of the Exercise
Shares quoted in the over-the-counter market in which the Exercise Shares are traded or the closing price quoted on any exchange
or electronic securities market on which the Exercise Shares are listed, whichever is applicable, as published in The Wall
Street Journal for the thirty (30) trading days prior to the date of determination of fair market value (or such shorter period
of time during which such Exercise Shares were traded over-the-counter or on such exchange). In the event that this Warrant is
exercised pursuant to this Section 4 in connection with the Company’s Initial Public Offering, the fair market value per
Exercise Share shall be the per share offering price to the public of the Company’s Initial Public Offering. If the Exercise
Shares are not traded on the over-the-counter market, an exchange or an electronic securities market, the fair market value shall
be the price per Exercise Share that the Company could obtain from a willing buyer for Exercise Shares sold by the Company from
authorized but unissued Exercise Shares, as such prices shall be determined in good faith by the Company’s Board of Directors.

 

    	 

    	 

    

 

5. Covenants
of the Company.

 

(a) Notices
of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose
of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash
dividends paid in previous quarters or a stock dividend) or other distribution, the Company shall mail to the Holder, at least
ten (10) days prior to such record date, a notice specifying the date on which any such record is to be taken for the purpose
of such dividend or distribution.

 

(b) Covenants
as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the
rights represented by this Warrant will, upon issuance in accordance with the terms hereof, be validly issued and outstanding,
fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further
covenants and agrees that the Company will at all times during the Exercise Period have authorized and reserved, free from preemptive
rights, a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights represented by this Warrant.
If at any time during the Exercise Period the number of authorized but unissued shares of Preferred Stock shall not be sufficient
to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary
to increase its authorized but unissued shares of Preferred Stock to such number of shares as shall be sufficient for such purposes.

 

(c) Registration
Rights. The provisions concerning piggyback registration of certain Registrable Securities held by the Holder that are set
forth on Exhibit 1 attached to this Warrant are incorporated into and made a part of this Warrant.

 

6. Adjustment
of Exercise Price and Number of Exercise Shares. The number and kind of Exercise Shares purchasable upon exercise of this
Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

 

(a) Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration of this
Warrant subdivide its Preferred Stock, by split-up or otherwise, or combine its Preferred Stock, or issue additional shares of
its Preferred Stock as a dividend with respect to any shares of its Preferred Stock, the number of Exercise Shares issuable on
the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately
decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price payable per share, but
the aggregate Exercise Price payable for the total number of Exercise Shares purchasable under this Warrant (as adjusted) shall
remain the same. Any adjustment under this Section 6(a) shall become effective at the close of business on the date the subdivision
or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon
the making of such dividend.

 

    	 

    	 

    

 

(b) Reclassification,
Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of
the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 6(a) above), then,
as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right
at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this
Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Exercise Shares by the Holder
immediately prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with
respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to
any shares of stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made
to the Exercise Price per Exercise Share payable hereunder, provided the aggregate Exercise Price shall remain the same.

 

(c) Notice
of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the
Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Exercise Shares
or other securities or property thereafter purchasable upon exercise of this Warrant.

 

7. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise
Price then in effect.

 

8. No
Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder
with respect to the Exercise Shares, including (without limitation) the right to vote such Exercise Shares, receive dividends
or other distributions thereon, exercise preemptive rights or be notified of stockholder meetings, and except as otherwise provided
in this Warrant or the Purchase Agreement, such Holder shall not be entitled to any stockholder notice or other communication
concerning the business or affairs of the Company.

 

9. Transfer
of Warrant. Subject to compliance with applicable federal and state securities laws and any other contractual restrictions
between the Company and the Holder contained in the Purchase Agreement (including but not limited to Sections 6.7 and 8.13), this
Warrant and all rights hereunder are transferable in whole or in part by the Holder to any person or entity upon written notice
to the Company. Within a reasonable time after the Company’s receipt of an executed Assignment Form in the form attached
hereto, the transfer shall be recorded on the books of the Company upon the surrender of this Warrant, properly endorsed, to the
Company at its principal offices, and the payment to the Company of all transfer taxes and other governmental charges imposed
on such transfer. In the event of a partial transfer, the Company shall issue to the new holders one or more appropriate new warrants.

 

10. Governing
Law; Arbitration. This Warrant shall be governed by and construed under the laws of the State of Delaware as applied to
agreements among Delaware residents, made and to be performed entirely within the State of Delaware. Any unresolved controversy
or claim arising out of or relating to this Warrant, except as (a) otherwise provided in this Warrant, or (b) any such controversies
or claims arising out of either party’s intellectual property rights for which a provisional remedy or equitable relief
is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be
reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association
(the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type
provided for in this Warrant and who is chosen by the AAA. The arbitration shall take place in Wilmington, Delaware, in accordance
with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered
in any court having jurisdiction thereof.

 

    	 

    	 

    

 

11. Successors
and Assigns. The terms and provisions of this Warrant and the Purchase Agreement shall inure to the benefit of, and be
binding upon, the Company and the holders hereof and their respective successors and assigns.

 

12. Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered
in construing or interpreting this Warrant.

 

13. Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during
normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications
shall be sent to the respective parties at the following addresses (or at such other addresses as shall be specified by notice
given in accordance with this Section 13):

 

	 	If
    to the Company:	Anebulo
    Pharmaceuticals, Inc.
	 	 	1415
    Ranch Road 620 South,
	 	 	Suite
    201
	 	 	Lakeway,
    Texas 78734
	 	 	Attention:
    CEO
	 	 	 
	 	If
    to Holder:	At
    the address shown on the signature page hereto.

 

14. Amendments
and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any term of this Warrant, the resolution of any
controversy or claim arising out of or relating to this Warrant and the provision of notice shall be conducted pursuant to the
terms of the Purchase Agreement.

 

15. Severability.
If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be excluded from this
Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms.

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Warrant as of the date first written above.

 

	 	ANEBULO
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/
    Daniel Schneeberger
	 	Name:	Daniel
    Schneeberger
	 	Title:	Chief Executive Officer
	 	 	 
	 	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	 	HOLDER:
	 	 	 
	 	22NW,
    LP
	 	 	 
	 	By:	/s/
    Aron English
	 	Name:	Aron
    English
	 	Title:	President
	 	Address:	1455
    NW Leary Way Suite 400
	 	 	Seattle,
    WA 98107

 

    	 

    	 

    

 

EXHIBIT
1 TO WARRANT

 

1. Definitions.
For purposes of this Exhibit:

 

1.1 “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under
common control with such Person, including without limitation any general partner, managing member, officer or director of such
Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members
of, or shares the same management company with, such Person.

 

1.2 “Damages”
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities
Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon: (a) any untrue statement or alleged untrue statement of a material fact contained in
any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments
or supplements thereto; (b) an omission or alleged omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading; or (c) any violation or alleged violation by the indemnifying party (or
any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation
promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.3 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.4 “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.5 “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

    	 

    	 

    

 

NOTICE
OF EXERCISE

 

ANEBULO
PHARMACEUTICALS, INC.

 

Attention:
Corporate Secretary

 

The
undersigned hereby elects to purchase, pursuant to the provisions of the Warrant, as follows:

 

	 	[  ]	__________
    shares of Preferred Stock pursuant to the terms of the attached Warrant, and tenders herewith payment in cash of the Exercise
    Price of such Exercise Shares in full, together with all applicable transfer taxes, if any.
	 	 	 
	 	[  ]	Net
    Exercise the attached Warrant with respect to __________ Exercise Shares.

 

The
undersigned hereby represents and warrants that Representations and Warranties in Section 6 of the Purchase Agreement are true
and correct as of the date hereof.

 

	 	 	 	HOLDER:
	 	 	 	 	 
	Date:	 	 	By:	 
	 	 	 	 	 
	 	 	 	Address:	      
	 	 	 	 	 
	 	 	 	 	 
	Name in which shares should be registered:	 	 	 
	 	 	 	 	 

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information.

Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name: __________________________________________________________________________________________ 

(Please
Print)

 

Address: ________________________________________________________________________________________

(Please
Print)

 

Dated: __________________________

 

Holder’s
Signature: ________________________________________________________________________________

 

Holder’s
Address: _________________________________________________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant. Officers of corporations
and those acting in a fiduciary or other representative capacity should provide proper evidence of authority to assign the foregoing
Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]